A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic...

por Klinghammer, K., Fayette, J., Kawecki, A., Dietz, A., Schafhausen, P., Folprecht, G., Rottey, S., Debourdeau, P., Lavernia, J., Jacobs, A., Ahrens-Fath, I., Dietrich, B., Baumeister, H., Zurlo, A., Ochsenreither, S., Keilholz, U.
Publicado 2021

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with ref...

por Ochsenreither, S., Fiedler, W.M., Conte, G.D., Macchini, M., Matos, I., Habel, B., Ahrens-Fath, I., Raspagliesi, F., Lorusso, D., Keilholz, U., Rolling, C., Kebenko, M., Klinghammer, K.F., Saavedra, O., Baumeister, H., Zurlo, A., Garralda, E.
Publicado 2022